Senores Pharmaceuticals Ltd Q2FY26 | 61% YoY Revenue Surge, 152% Profit Jump, and an Atlanta Factory Growing Faster Than a Startup’s Burn Rate
1. At a Glance
Welcome to the blockbuster episode of “Pharma ne kaha, main complex hoon”—starring Senores Pharmaceuticals Ltd (SPL), India’s latest generics-to-global glamour story. The stock closed at ₹805 on 6th Nov 2025, giving a six-month return of 65.7% and a three-month joyride of 23.4%, while the rest of the midcap pharma pack was still busy explaining “supply chain disruptions.”
The company’s Q2FY26 performance was the kind of flex you post on LinkedIn:
Revenue: ₹162 crore (+61% YoY)
PAT: ₹30.1 crore (+152% YoY)
Operating Margin: A cool 31%
EPS: ₹7.03 (annualised ₹28.12)
Stock P/E: 42.5x (Industry avg: 32.5x, so yes, a premium for swagger)
With a market cap of ₹3,706 crore, ROE at 11.8%, and zero pledges, Senores isn’t your usual sleepy smallcap—this one’s busy throwing USFDA-approved ANDAs around like confetti at a pharma wedding.
But the real juice? They’ve acquired 14 ANDAs from Dr. Reddy’s, bought Teva’s two complex generics, opened a second API plant in Gujarat, and are now expanding their Atlanta facility to double capacity. Clearly, this is not a “small pharma”—it’s a startup disguised as a generics empire.
2. Introduction
Imagine a company born in 2015, barely old enough to qualify as a millennial, but already behaving like a multinational boomer. That’s Senores Pharmaceuticals—a global research-driven pharma player that walked into the US, Canada, and UK markets wearing FDA-approved shoes while most Indian pharma firms were still polishing their DRHPs.
With 43-country presence and two factories—one in Ahmedabad (India) and another in Atlanta (USA)—Senores has the rare distinction of being that Indian kid who made it big abroad before the local mohalla even noticed.
They aren’t selling vanilla paracetamol. Nope. Senores makes complex generics, critical care injectables, and APIs, focusing on underpenetrated molecules that scare away the competition because, well, chemistry is hard.
If pharma were a college fest, Senores would be that overachieving student who wins the coding hackathon and the dance competition. They’re doing CDMO/CMO work in the US, branded generics in India, and API manufacturing for SAARC. All this, while juggling 70 approved ANDAs and 57 pipeline products.
The question isn’t whether Senores is growing—it’s whether the company’s caffeine budget is under control.
3. Business Model – WTF Do They Even Do?
Let’s decode the maze. Senores operates across four primary business lines:
Regulated Markets (65% of Q1FY26 revenue) Think of this as their elite gym membership—FDA-certified manufacturing for the US, UK, and Canada. Their Atlanta facility is the star: 1.2 billion OSD units capacity, soon to be 2 billion post-expansion. They sell under their own ANDAs or partner as a CDMO/CMO—basically, they either make your medicine or your competitor’s medicine, whoever pays first.
Emerging Markets (21%) This is the jugaad division—a WHO-GMP-approved Chhatral facility producing 308 registered products for regions where healthcare budgets are smaller but demand is explosive (read: Africa, Middle East, Asia).
API Business The Naroda facility makes 16 commercial APIs. They even inaugurated their second API plant in Gujarat (Feb 2025)—because why buy raw material when you can manufacture it and flex on LinkedIn with “backward integration achieved”?
Branded Generics (14%) In India, Senores sells critical care injectables under its own brand, supported by 82 field staff. Not exactly Cipla-scale, but hey, they’re learning to hustle domestically too.
Their R&D setup is split like an NRI marriage—US handles innovation, India handles paperwork. Between 97+ formulations and 37 pipeline CGT opportunities, Senores seems to have its fingers in every molecule that ends with “-zole,” “-mab,” or “-vir.”
Commentary: This isn’t just growth—it’s a gym transformation reel. In four quarters, revenue nearly doubled, margins bulked up from 17% to 31%, and profit tripled. Even the taxman must’ve fainted looking at that 152% PAT growth.
5. Valuation Discussion – Fair Value Range Only
Let’s get nerdy.
(a) P/E Method Industry PE = 32.5x EPS (TTM) = ₹18.9 → Fair value range = ₹18.9 × (30–35) = ₹567 – ₹662
(b) EV/EBITDA Method EV = ₹3,745 Cr EBITDA (TTM) = ₹129 Cr EV/EBITDA = 29x Peer average = 22–25x
